Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis

被引:62
作者
Czaja, AJ
Carpenter, HA
机构
[1] Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, Rochester, MN 55905 USA
关键词
pathogenic mechanisms; plasma cells; relapse;
D O I
10.1034/j.1600-0676.2003.00810.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Relapse of type 1 autoimmune hepatitis after drug withdrawal may relate to incomplete histological improvement during corticosteroid therapy and/or persistence of pathogenic mechanisms. Aim: Determine the histological features prior to drug withdrawal that are associated with relapse in patients satisfying pre-established clinical, laboratory, and histological criteria for remission and relapsing after corticosteroid withdrawal. Methods: One hundred liver tissue samples obtained immediately prior to corticosteroid withdrawal from 88 patients who had previously satisfied criteria for histological remission were reviewed retrospectively. Results: Histological findings in the patients who relapsed were similar to those in the patients who sustained remission in regard to histological activity index (1.7 +/- 0.1 versus 1.6 +/- 0.2, P = 0.6), fibrosis score (2.6 +/- 0.3 versus 2.3 +/- 0.4, P = 0.5), and frequencies of interface hepatitis (36% versus 20%, P = 0.2), cirrhosis (21% versus 17%, P = 0.8), and normal or near normal tissue (9% versus 7%, P > 0.9). Only the presence of portal plasma cells was associated with relapse (31% versus 7%, P = 0.01). The positive predictability of portal plasma cell infiltration for relapse was 92%, but its sensitivity was only 31%. Conclusions: Portal plasma cell infiltration is predictive of relapse after drug withdrawal in tissue specimens already satisfying criteria for remission. Portal plasma cell infiltration may be indicative of an active antibody-dependent pathogenic mechanism. Its low sensitivity for relapse indicates the need for other complementary predictors of outcome.
引用
收藏
页码:116 / 123
页数:8
相关论文
共 46 条
  • [1] Almawi WY, 2001, MOD ASP IMMUNOBIOL, V2, P78
  • [2] International Autoimmune Hepatitis Group Report:: review of criteria for diagnosis of autoimmune hepatitis
    Alvarez, E
    Berg, PA
    Bianchi, FB
    Bianchi, L
    Burroughs, AK
    Cancado, EL
    Chapman, RW
    Cooksley, WGE
    Czaja, AJ
    Desmet, VJ
    Donaldson, RT
    Eddleston, ALWF
    Fainboim, L
    Heathcote, J
    Homberg, JC
    Hoofnagle, JH
    Kakumu, S
    Krawitt, EL
    Mackay, IR
    MacSween, RNM
    Maddrey, WC
    Manns, MP
    McFarlane, IG
    zum Büschenfelde, KHM
    Mieli-Vergani, G
    Nakanuma, Y
    Nishioka, M
    Penner, E
    Porta, G
    Portmann, BC
    Reed, WD
    Rodes, J
    Schalm, SW
    Scheuer, PJ
    Schrumpf, E
    Seki, T
    Toda, G
    Tsuji, T
    Tygstrup, N
    Vergani, D
    Zeniya, M
    [J]. JOURNAL OF HEPATOLOGY, 1999, 31 (05) : 929 - 938
  • [3] CYTOKINE PROFILE OF VIRAL AND AUTOIMMUNE CHRONIC ACTIVE HEPATITIS
    ALWABEL, A
    ALJANADI, M
    RAZIUDDIN, S
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1993, 92 (06) : 902 - 908
  • [4] Non-Th2 regulatory T-cell control of Th1 autoimmunity
    Bach, JF
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2001, 54 (1-2) : 21 - 29
  • [5] Cytokine modulation by glucocorticoids: Mechanisms and actions in cellular studies
    Brattsand, R
    Linden, M
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 : 81 - 90
  • [6] Carpenter Herschel A, 2002, Clin Liver Dis, V6, P685, DOI 10.1016/S1089-3261(02)00022-3
  • [7] COCHRANE AMG, 1976, LANCET, V1, P441
  • [8] IMMUNOCYTOCHEMICAL STUDY OF GAMMA-GLOBULIN IN LIVER IN HEPATITIS AND POSTNECROTIC-CIRRHOSIS
    COHEN, S
    OHTA, G
    SINGER, EJ
    POPPER, H
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1960, 111 (02) : 285 - +
  • [9] AUTOIMMUNE HEPATITIS - EVOLVING CONCEPTS AND TREATMENT STRATEGIES
    CZAJA, AJ
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (02) : 435 - 456
  • [10] Drug therapy in the management of type 1 autoimmune hepatitis
    Czaja, AJ
    [J]. DRUGS, 1999, 57 (01) : 49 - 68